Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age12-65
SponsorChinese PLA General Hospital
About this trial
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.
Eligibility criteria
Qualifiers
high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;
Have matched sibling donors, ≥8/10 HLA matched unrelated donors or haploidentical donors
All patients should aged 12 to 65 years;
Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;
Disqualifiers
pregnant women;
Patients with mental illness or other states unable to comply with the protocol;
ALL patients with Ph positive;
Trial design
Treatments tested in this trial
- Ruxolitinib combined with Chidamide.
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov